Form 4: Medifast Director Andrea B. Thomas Receives Stock Grant

Director Andrea B. Thomas acquired 11,680 restricted stock units as part of her annual director fee compensation.

Summary

• Director Andrea B. Thomas was granted 11,680 restricted stock units (RSUs) on May 26, 2026.
• The grant was issued under the Medifast, Inc. Director's Deferred Compensation Plan.
• Each unit represents the right to receive one share of common stock.
• The total beneficial ownership for the director following this transaction is 35,697.123 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• The director's equity stake in the company has increased, aligning her interests with those of shareholders.

Negatives

• None identified.

Risks

• The vesting of these shares is subject to the terms of the 2012 Share Incentive Plan and the Director's Deferred Compensation Plan.

Future Outlook

The granted restricted stock units are scheduled to vest in full on May 26, 2027.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of deferred compensation plans for director fees is consistent with standard practices among mid-cap consumer health and wellness companies.

Stakeholder Impact

• Shareholders benefit from increased director alignment with company equity performance.

Next Steps

• Vesting of the 11,680 restricted stock units on May 26, 2027.

Key Dates

Keywords

Medifast, MED, Form 4, Insider Trading, Director Compensation, Equity Grant